- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Imron Aly, JD: The Issues at Stake in Oil States
Speaking with the The Center for Biosimilars® the day before the Supreme Court of the United States ruled in Oil States Energy Services, LLC, v Greene’s Energy Group, LLC, Imron Aly, JD, partner at Schiff Hardin, LLP, explained the issues at stake in the case.
Transcript:
What are some of the issues at stake in the Oil States case?
So what that will end up meaning is, 1 of 3 things could happen. One, the Supreme Court could say that [inter partes reviews, IPRs] are not constitutional, and that means that no one can use that way to challenge validity of a patent. The second thing that could happen is the same thing, but only for a prospective, going forward, nature—saying that what’s happened has happened, but going forward, no one can use that system. Third—what I think most people are predicting would be likely to happen—is that the Supreme Court would say, they’re constitutional, and perhaps limited in certain ways of executing them, or requiring procedural safeguards for when and how they’re used, but that they’re likely to be constitutional. So those are some of the issues at stake.
PBM Evolution Toward Value-Based Care Shifts to Transparent Pharmacy Pricing
March 30th 2025Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, predict pharmacy benefit managers (PBMs) will evolve toward value-based care, mirroring the broader shift toward open-cost structures.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
